Rectal Cancer: NRG-GI002

NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer


The purpose of this study is to learn if adding an experimental drug, veliparib (also known as ABT-888), to a usual treatment is better than the usual treatment alone for people with locally advanced rectal cancer. To be better than the usual treatment, the addition of the experimental drug to the usual treatment needs to shrink more of the cancer than the usual treatment alone.

Another purpose of this study is to test the good and bad effects of veliparib when added to the usual treatment. Veliparib may shrink the cancer but it can also cause side effects. Veliparib is not FDA-approved for treating cancer but it is being used in other clinical trials.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
NRG Oncology
Kim Turner, R.N. at 563-421-1908


  • Genesis Medical Center, West Central Park
    1401 West Central Park Avenue
    Davenport, IA 52804
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office